Figure 4 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Imianowski CJ., Kuo P., Whiteside SK., von Linde T., Wesolowski AJ., Conti AG., Evans AC., Baird T., Morris BI., Fletcher NE., Yang J., Poon E., Lakins MA., Yamamoto M., Brewis N., Morrow M., Roychoudhuri R.
<p>The antitumor efficacy of OX40/CD137 dual agonism is dependent upon IFNγ signaling. <b>A,</b> Schema representing treatment schedule of FS120m and anti-IFNγ. <b>B,</b> Tumor measurements at indicated timepoints after MC38 tumor implantation of the mice described in <b>A</b>. <b>C,</b> Representative plots from the tumor (left) and spleen (right) showing IFNγ<sup>+</sup> cells in CD8<sup>+</sup> T cells and indicated CD4<sup>+</sup> T-cell populations from mice receiving the specified treatment. <b>D,</b> Replicate values of IFNγ<sup>+</sup> cells in CD8<sup>+</sup> T cells and the indicated CD4<sup>+</sup> T-cell populations from the tumor, spleen, and tumor-draining lymph node of mice receiving the specified treatment. Data were analyzed by two-way ANOVA with Tukey correction for multiple comparisons (<b>B</b>) and ordinary one-way ANOVA with Tukey correction for multiple comparisons (<b>D</b>). Bars and error are mean and SEM. *, <i>P</i> ≤ 0.05; **, <i>P</i> ≤ 0.01; ***, <i>P</i> ≤ 0.001; ****, <i>P</i> ≤ 0.0001. Ctrl, control; dLN, tumor-draining lymph node; MFI, mean fluorescence intensity.</p>